<?xml version='1.0' encoding='utf-8'?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-title>Journal of Pioneering Medical Sciences</journal-title></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/jpms202615S0231</article-id><article-categories>Review Article</article-categories><title-group><article-title>Global Evidence on Undiagnosed and Uncontrolled Hypertension: A Systematic Review and Meta-analysis of Population-Based Studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Salih</surname><given-names>Islam Mohammedien Abbas</given-names></name><xref ref-type="aff" rid="aff1" /><email>I.salih@mu.edu.sa</email></contrib></contrib-group><aff id="aff1"><institution>Department of Internal Medicine, College of Medicine, Majmaah University, Al-Majma'ah 11952, Saudi Arabia</institution></aff><abstract>Background: Hypertension care involves distinct stages of diagnosis, treatment, and blood pressure control. We synthesized population-based evidence on undiagnosed and uncontrolled hypertension and related care indicators across the settings represented by eligible studies. Methods: This systematic review included 25 observational articles reporting measured blood pressure and extractable denominators for at least one hypertension care outcome. Separate random-effects meta-analyses of logit-transformed proportions were undertaken for undiagnosed hypertension, uncontrolled hypertension among treated participants, uncontrolled hypertension among all participants with hypertension, awareness/diagnosis, treatment, and blood pressure control. Search end date: (VERIFY LAST SEARCH DATE0. Risk of bias was assessed using AXIS or the Newcastle&amp;ndash;Ottawa Scale, as applicable. Results: The pooled proportion undiagnosed among participants meeting study-specific hypertension definitions was 46.4% (95% CI 42.8&amp;ndash;50.1%; I&amp;sup2;=99.7%). Uncontrolled blood pressure was estimated separately among treated hypertensive participants (49.6%; 95% CI 37.2&amp;ndash;62.1%; I&amp;sup2;=99.5%) and among all hypertensive participants (78.7%; 95% CI 71.2&amp;ndash;84.6%; I&amp;sup2;=99.9%). In different evidence subsets, pooled awareness/diagnosis, treatment, and control were 52.5% (95% CI 47.3&amp;ndash;57.7%; I&amp;sup2;=99.7%), 43.5% (95% CI 37.4&amp;ndash;49.8%; I&amp;sup2;=99.8%), and 21.3% (95% CI 15.4&amp;ndash;28.8%; I&amp;sup2;=99.9%), respectively. These estimates are not sequential observations from one cohort and cannot be directly subtracted. Study-specific narrative findings suggested variation by sex, age, residence, and socioeconomic conditions, but these associations were not established by a pooled subgroup analysis. Funnel-plot tests did not show statistically significant asymmetry for most pools; Egger and Begg tests gave discordant findings for uncontrolled hypertension among treated participants. Extreme heterogeneity limits generalizability. Conclusion: In the included study populations, approximately 46% of participants with hypertension were undiagnosed and approximately 79% had uncontrolled blood pressure when all hypertensive participants formed the denominator. These separately pooled, highly heterogeneous proportions are not universal country-level estimates. Consistent hypertension definitions, standardized surveillance, and clearly specified denominators are needed to interpret diagnosis, treatment, and control gaps.</abstract><kwd-group><kwd>Hypertension</kwd><kwd>Undiagnosed Hypertension</kwd><kwd>Uncontrolled Hypertension</kwd><kwd>Awareness</kwd><kwd>Treatment</kwd><kwd>Blood Pressure Control</kwd><kwd>Prevalence</kwd><kwd>Meta-Analysis</kwd></kwd-group><history><date date-type="received"><day>6</day><month>8</month><year>2026</year></date></history><history><date date-type="revised"><day>1</day><month>9</month><year>2026</year></date></history><history><date date-type="accepted"><day>1</day><month>10</month><year>2026</year></date></history><pub-date><date date-type="pub-date"><day>15</day><month>11</month><year>2026</year></date></pub-date><license license-type="open-access" href="https://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.</license-p></license></article-meta></front><body><sec><title>INTRODUCTION</title><p>Hypertension continues to be one of the most significant preventable factors behind the development of cardiovascular morbidity and early mortality. Not only the importance of hypertension is connected to the high population prevalence, but also to its long-lasting asymptomatic nature, when damage is done to the vessels, kidneys, brain, and heart even before the treatment or detection of the condition is performed [1]. Blood pressure elevation has been shown to correlate with the development of stroke, ischemic heart disease, heart failure, chronic kidney disease, cognitive disorders, and all-cause mortality [2]. Thus, it is crucial to detect hypertension and reduce it properly since there are inexpensive diagnostic tests and effective antihypertensive treatments available [3].
&amp;nbsp;
In recent decades, there has been a considerable shift in the epidemiology of hypertension due to population aging, urbanization, diet change, decreased physical activity,&amp;nbsp;obesity, diabetes, and increased cardiometabolic risk burden [4]. These trends have been especially notable in low- and middle-income areas where the health-care system should be able to manage infectious diseases along with the rise of chronic diseases, lack of general practitioner availability and limited access to the drugs for long-term management [5]. In high-income settings, the detection and management of hypertension have improved, however, the control is still uneven depending on the availability to the health care, socioeconomic status, age, gender, ethnicity and continuity of care [6]. Therefore, the global hypertension burden cannot be estimated based only on the prevalence data, but it should be considered within the diagnosis-awareness-treatment-control cascade of care.
&amp;nbsp;
Undetected hypertension can be viewed as a failure of early detection. People with elevated blood pressure that are unaware about their condition do not enter the cardiovascular prevention program, do not receive the lifestyle advice, pharmacological treatment, and regular monitoring [7]. The burden of undetected hypertension tends to be higher in males, younger people, rural population, people with lower income, lesser education level and poor access to the health-care services [8]. This pattern suggests that the issue of undetected hypertension is not just biological but reflects the underlying structural inequities, access to the health-care service, screening coverage, and health-seeking behavior. As hypertension is usually asymptomatic, the opportunistic detection might not be enough in populations with insufficient primary care attendance and low perceived disease burden [9].
&amp;nbsp;
Additionally, uncontrolled hypertension is a particular public health problem that can happen among the population that was never diagnosed with hypertension, among those that were diagnosed but not treated and among those that were being treated but have insufficient blood pressure levels [10]. Poor blood pressure control might be caused by the insufficient treatment initiation, poor adherence to the drugs, therapeutic inertia, lack of follow-ups, drug cost, fragmented care or insufficient treatment intensification [11-12]. Thus, uncontrolled hypertension reflects the failures across the whole care cascade, from screening to effective treatment. The analysis of uncontrolled hypertension together with undetected hypertension allows assessing the cardiovascular prevention gaps more comprehensively.
&amp;nbsp;
Prior national and multinational studies have reported substantial variation in hypertension awareness, treatment, and control. Differences in sampling, blood pressure measurement, diagnostic thresholds, survey years, and outcome denominators complicate direct comparison. This review therefore aimed primarily to synthesize separately the proportions of undiagnosed hypertension among hypertensive participants and uncontrolled hypertension among (a) treated hypertensive participants and (b) all hypertensive participants. Secondary objectives were to summarize awareness/diagnosis, treatment, and blood pressure control across eligible population-based studies, and to describe study-specific demographic patterns. Because the included studies cover selected countries and multinational samples rather than every world region, the findings represent global evidence across sampled settings, not a geographically representative worldwide prevalence estimate.</p></sec><sec><title>METHODS</title><p>Review Design
The review protocol was designed following the PECOS design template and formulated following PRISMA 2020 reporting guidelines [13] for systematic review reporting. The population criterion was human subjects from general population, community-based, national survey, or multi-country epidemiological databases. Exposure was hypertension using measured blood pressure, prior diagnosis, use of antihypertensive drugs, or study-specific hypertension definitions. A traditional comparator was not required since the review focused on estimating pooled prevalence; however, comparative stratification was considered by country, region, income level, age group, gender, and stage of the healthcare cascade. Outcomes were undiagnosed hypertension, uncontrolled hypertension, awareness/diagnosis, treatment, and blood pressure control. Eligible study designs were original human observational studies, which included cross-sectional surveys, repeat national surveys, population-based cohort baseline analyses, and multi-country epidemiological studies since these designs had appropriate prevalence denominators and measured blood pressure data.
&amp;nbsp;
Protocol registration and amendments: (VERIFY WHETHER REGISTERED IN PROSPERO/OSF; PROVIDE IDENTIFIER OR STATE NOT REGISTERED). (VERIFY WHETHER ELIGIBILITY CRITERIA AND ANALYSES WERE SET BEFORE SCREENING AND DESCRIBE ANY AMENDMENTS). The review synthesizes independent outcome-specific proportions; an article contributing multiple survey rounds or populations requires assessment for overlap before inclusion in any single pool.
&amp;nbsp;
Inclusion and Exclusion Criteria
Outcome-specific eligibility: Undiagnosed hypertension required the number of previously unaware or undiagnosed individuals among all individuals meeting the source study&amp;rsquo;s hypertension definition. Uncontrolled hypertension among treated participants required uncontrolled cases among participants currently receiving antihypertensive treatment. Uncontrolled hypertension among all hypertensive participants required uncontrolled cases among all hypertensive participants, including untreated or undiagnosed cases where the source definition allowed. Awareness/diagnosis, treatment, and control were pooled only where numerator and denominator matched the stated outcome. Mixed samples, survey-weighted percentages, age-standardized estimates, and repeated survey waves require source-by-source denominator and independence checks (VERIFY AGAINST EXTRACTION SHEET).
&amp;nbsp;
Included studies should have been original human studies reporting either undiagnosed hypertension, uncontrolled hypertension, or sufficient awareness, treatment, and control data from which these outcomes can be derived. Eligible studies were cross-sectional studies, national health surveys, WHO STEPS-based surveys, Demographic and Health Survey analyses, population-based cohort analyses, and multi-country community-based epidemiological studies. Included studies should report either measured blood pressure, clearly stated definition of hypertension, and an extractable denominator for at least one relevant pooled outcome. The exclusion criteria were systematic reviews, meta-analyses, narrative reviews, editorials, letter to the editor (with no new data), case reports, case series (without valid prevalence denominators), animal studies, in vitro studies, and intervention studies without baseline prevalence data. In addition, the review excluded studies that focused only on hospital inpatients, clinic-only hypertensive patients, disease-specific populations, occupation-specific samples, students only, and immigrants only because they are not appropriate for general population-level hypertension burden.
&amp;nbsp;
Search Reproducibility
(VERIFY EXACT SEARCH DATES, SEARCH END DATE, LANGUAGE AND DATE RESTRICTIONS, GOOGLE SCHOLAR SCREENING LIMITS, GREY-LITERATURE COVERAGE, AND DEDUPLICATION METHOD). The listed PubMed query requires both awareness-related and treatment/control-related terms and may have missed studies reporting only one outcome. This potential limitation should be considered when interpreting coverage; a corrected search and updated flow counts must not be claimed without rerunning the search. Embase, Scopus, and Web of Science were not listed among the searched databases.
&amp;nbsp;
Database Search Protocol
Literature was searched using database-specific Boolean combinations of hypertension, undiagnosed disease, awareness, treatment, control, prevalence, and population-based epidemiology on PubMed, Cochrane Library, Dimensions, and Google Scholar (Table 1). PubMed literature was searched using MeSH terms in conjunction with title/abstract keywords. On the other hand, Cochrane library literature search used more controlled vocabulary and trial/indexing while avoiding reviews. In addition, dimensions were used to expand literature searches for global public health and survey-based literature. Google Scholar was used with broad phrase combinations in order to find epidemiological studies, national survey reports, and multi-country databases.
&amp;nbsp;
Table 1: Search Strings Utilised Across the Databases




Database


Search string




PubMed/MEDLINE


("Hypertension"[MeSH] OR hypertension[tiab] OR "high blood pressure"[tiab] OR "raised blood pressure"[tiab] OR "elevated blood pressure"[tiab]) AND ("Undiagnosed Diseases"[MeSH] OR undiagnosed[tiab] OR "undiagnosed hypertension"[tiab] OR unaware[tiab] OR awareness[tiab] OR diagnosis[tiab] OR diagnosed[tiab]) AND ("Blood Pressure Determination"[MeSH] OR "blood pressure measurement"[tiab] OR measured[tiab]) AND ("Prevalence"[MeSH] OR prevalence[tiab] OR epidemiology[tiab] OR "population-based"[tiab] OR "community-based"[tiab] OR "national survey"[tiab] OR "cross-sectional"[tiab]) AND (treatment[tiab] OR control[tiab] OR "blood pressure control"[tiab] OR "uncontrolled hypertension"[tiab] OR "care cascade"[tiab]) NOT (review[pt] OR meta-analysis[pt] OR editorial[pt] OR letter[pt] OR animals[mh] NOT humans[mh])




Cochrane Library


(hypertension OR "high blood pressure" OR "raised blood pressure"),ab,kw AND (undiagnosed OR unaware OR awareness OR diagnosis OR "uncontrolled hypertension" OR "blood pressure control" OR treatment),ab,kw AND (prevalence OR epidemiology OR "population based" OR "community based" OR "national survey" OR "cross sectional" OR "health survey"),ab,kw NOT ("systematic review" OR "meta-analysis" OR protocol OR animal),ab,kw




Dimensions


(hypertension OR "high blood pressure" OR "raised blood pressure" OR "elevated blood pressure") AND ("undiagnosed hypertension" OR undiagnosed OR unaware OR awareness OR "hypertension diagnosis" OR "uncontrolled hypertension" OR "blood pressure control" OR treatment) AND (prevalence OR epidemiology OR "population-based" OR "community-based" OR "nationally representative" OR "national survey" OR "WHO STEPS" OR "Demographic and Health Survey" OR "cross-sectional study") AND NOT ("systematic review" OR "meta-analysis" OR "narrative review" OR "case report" OR animal OR "in vitro")




Google Scholar


allintitle: hypertension prevalence awareness treatment control OR "undiagnosed hypertension" "population-based" OR "uncontrolled hypertension" "community-based" OR "hypertension awareness treatment control" "national survey" OR "hypertension care cascade" "measured blood pressure" OR "WHO STEPS" hypertension awareness treatment control OR "Demographic and Health Survey" "undiagnosed hypertension"




&amp;nbsp;
Data Harmonization
For each outcome, denominators must be checked against the original publication before pooling. When numerators were reconstructed from reported percentages, rounding may have introduced error, particularly for survey-weighted or rounded estimates. Complements (for example, 100% minus awareness or control) are valid only when the original numerator and denominator refer to the same population and definitions. (VERIFY WHETHER TWO REVIEWERS EXTRACTED DATA INDEPENDENTLY AND HOW DISCREPANCIES WERE RESOLVED). A study-level extraction table should report the original or derived numerator, denominator, hypertension threshold, measurement protocol, survey weighting, and source of each estimate.
&amp;nbsp;
Protocol for Data Extraction and Data Items
The AXIS and Newcastle&amp;ndash;Ottawa judgments shown in Figures 2 and 3 describe study-specific methodological concerns; they do not establish that pooled estimates are unbiased. (VERIFY INDEPENDENT ASSESSMENT, THE EXACT NOS VERSION, AND RULES USED TO CONVERT DOMAIN RATINGS INTO OVERALL JUDGMENTS). Full domain-level ratings should be supplied as supplementary material.
&amp;nbsp;
Data were extracted from each article using a pre-defined standard data abstraction form. Study-level variables region, study design, source of data, sampling method, study period, age eligibility, sample size, mean/median age, percentage of males, setting, length of follow-up if any, and population representativeness. Methodological variables abstracted included method of blood pressure measurement, number of readings, BP averaging technique, diagnostic threshold for hypertension, definition of hypertension, definition of undiagnosed hypertension, definition of uncontrolled hypertension, definition of awareness, definition of treatment, definition of BP control, covariates of interest, and statistical methods used. Outcome variables abstracted included number of hypertensive participants, number of undiagnosed cases, number of diagnosed or aware cases, number of treated cases, number of controlled cases, number of uncontrolled cases, pooled proportion, 95% CI, and type of denominator. In cases where the articles provided proportions without the number of events, the numerators were reconstructed using the published denominator size and rounded to integers.
&amp;nbsp;
GRADE Interpretation
The very high inconsistency across all six outcomes and differences in definitions, survey populations, and measurement protocols warrant explicit consideration when rating certainty. Precision of a pooled confidence interval does not by itself establish high certainty. [VERIFY AND INSERT OUTCOME-SPECIFIC GRADE JUDGMENTS AND JUSTIFICATIONS FROM THE ACTUAL ASSESSMENT; DO NOT INFER FORMAL RATINGS FROM I&amp;sup2; ALONE].
&amp;nbsp;
Assessment of Risk of Bias
Bias risk was assessed in cross-sectional evidence using the AXIS tool [14] and cohort or longitudinal evidence using the Newcastle-Ottawa Scale. The assessment criteria in the AXIS tool included clarity of study aims, appropriateness of study design, representativeness of sampling strategy, justification of sample size, validity of blood pressure measurement, clarity of outcome definitions, handling of non-responses, statistical reporting, and agreement between results and conclusion. The Newcastle-Ottawa Scale [15] assessment was based on criteria related to the selection of participants, comparability of exposed and unexposed groups, ascertaining the outcome of interest, adequacy of follow up, and controlling for potential confounders. Studies that used probability sampling, standardized blood pressure measurement, had clear diagnostic criteria, had extractable denominators, and full reporting of the outcome of interest were rated as low bias risk studies. The ones that used convenience sampling, non-standardized blood pressure measurement, did not provide denominators, and inadequate adjustment for confounders were rated as high methodological risk.
&amp;nbsp;
Funnel-plot asymmetry tests are difficult to interpret when heterogeneity is extreme and the number of estimates is limited. A nonsignificant result does not demonstrate absence of publication bias. For uncontrolled hypertension among treated participants, Egger&amp;rsquo;s and Begg&amp;rsquo;s tests gave discordant signals; these should be described as inconclusive. [VERIFY THE REPEATED EGGER INTERCEPT/P-VALUE ENTRIES FOR THE ALL-HYPERTENSIVE UNCONTROLLED AND CONTROL POOLS AGAINST ORIGINAL OUTPUT].
&amp;nbsp;
GRADE Certainty Assessment
Leave-one-out analysis measures the influence of omitting one estimate at a time but does not resolve incompatible outcome definitions, correlated study samples, or extreme between-study heterogeneity. The awareness and treatment pools were moderately sensitive to selected omissions. [VERIFY TABLES 5&amp;ndash;6 ARITHMETIC, SOURCE OF INFLUENCE, AND ANY RISK-OF-BIAS OR DEFINITION-RESTRICTED SENSITIVITY ANALYSES BEFORE CLAIMING ROBUSTNESS].
&amp;nbsp;
The certainty of evidence was assessed using the GRADE approach [16] in combination with the AXIS [14] and NOS assessments [15] of risk of bias. Since the evidence base was dominated by observational prevalence studies, the initial certainty was taken to be low and then was graded taking into consideration risk of bias, inconsistency, indirectness, imprecision, and publication bias. Low certainty was determined by studies with unclear sampling method, non-standardized blood pressure measurement, incompatible definitions of denominator, very high heterogeneity, very large confidence interval, and asymmetric funnel plots. Certainty was not reduced by indirectness if the studies sampled the general population/community populations with measured blood pressure. Large nationally-representative and multi-country studies enhanced confidence in the findings even though heterogeneity was considerable in pooled estimates of single global pool.
&amp;nbsp;
Meta-Analytic Specification Requiring Verification
{INSERT EXACT SOFTWARE VERSION, RANDOM-EFFECTS TAU-SQUARED ESTIMATOR, CONFIDENCE-INTERVAL METHOD, ZERO-EVENT HANDLING, AND STUDY-WEIGHT CALCULATION FROM ORIGINAL ANALYSIS}. For a study with x events among n eligible participants, the unadjusted proportion is p=x/n and its logit is log[p/(1&amp;minus;p)]; inverse-logit back-transformation is exp(&amp;theta;)/(1+exp(&amp;theta;)). These expressions describe the transformation but do not establish which variance estimator or continuity correction the original software applied. With I&amp;sup2;=99.5%&amp;ndash;99.9%, the pooled proportions are averages of markedly different settings; a prediction interval or appropriately stratified analyses would be preferable if supported by the underlying data.
&amp;nbsp;
Protocol for Publication Bias Assessment
Publication bias and small study effects were evaluated using the funnel plot where there were at least ten estimates available for the pool of an outcome. Each funnel plot included the individual study-specific transformed prevalence estimate and standard error with pseudo-95% confidence intervals around the pooled effect. Asymmetry of the funnel plot was visually and statistically assessed using the Egger regression test and Begg&amp;rsquo;s rank correlation test. A p-value below 0.05 was considered as evidence of statistical asymmetry.
&amp;nbsp;
The Study-Selection Arithmetic is Internally Consistent
725 identified minus 48 duplicates equals 677 screened; 677 minus 59 exclusions equals 618 reports sought; 618 minus 26 unretrieved equals 592 assessed; and 592 minus 567 excluded equals 25 included. The PRISMA figure should be checked for complete exclusion-reason categories, documentation of retrieval attempts, and whether each report corresponds to one independent study population. {VERIFY SEARCH END DATE AND WHETHER ANY REPEATED SURVEY POPULATIONS WERE COUNTED MORE THAN ONCE}.
&amp;nbsp;
Sensitivity Analysis Protocol
Leave-one-out sensitivity analysis was carried out to test the robustness of the pooled effect size. This involved taking one of the estimates for each study included in the meta-analysis model and recalculating the pooled proportion, 95% CI, and heterogeneity statistics, with each estimate being left out at once. The influence of the studies on the results was determined by comparing their recalculated estimates to the primary pooled estimates and identifying those that caused maximum change in the pooled proportion.
&amp;nbsp;
Meta-Analysis Protocol
Meta-analysis was conducted using the Meta-Analysis Online tool [17] for pooled proportions. Pooled random-effect models were run separately for undiagnosed hypertension, uncontrolled hypertension in those under treatment, uncontrolled hypertension in all hypertensive subjects, awareness/diagnosis, treatment, and blood pressure control. Logit transformations were applied to proportions in order to stabilize variance and the pooled estimate was back-transformed to calculate the percentage with 95% CI. The random effects model was chosen because of expected clinical and methodological heterogeneity across different countries, age groups, survey platform, blood pressure measurement protocols, and healthcare systems. Heterogeneity was quantified using Cochran&amp;rsquo;s Q, I&amp;sup2;, and &amp;tau;&amp;sup2; statistics. Forest plot was generated for all pooled domains with at least three eligible study estimates. Publication bias was analyzed using funnel plots, Egger&amp;rsquo;s and Begg&amp;rsquo;s tests where applicable.</p></sec><sec><title>RESULTS</title><p>A total of 725 records were identified from PubMed, Cochrane Library, Dimensions, and Google Scholar in the initial phase of the database search, with no further records being obtained from the registers. After excluding 48 duplicates, 677 records were screened for titles and abstracts, of which 59 records were excluded due to not being in accordance with the PECOS for this review. Then, 618 records were sought for retrieval, of which 26 could not be retrieved. Out of 592 records, 567 reports were excluded due to being case reports, literature reviews, and editorials. Eventually, 25 studies [18-42] were found eligible and selected for the systematic review and quantitative synthesis (Figure 1).
&amp;nbsp;

&amp;nbsp;
Figure 1: PRISMA Representation of Study Inclusion Process
&amp;nbsp;
Bias Assessment Observations
In the combined risk-of-bias assessment of the included cross-sectional studies (Figure 2), it was seen that most cross-sectional studies had low overall risk of bias, including [18-21,23-25,27,29,30,31-33,35-40,42]. However, there were some cross-sectional studies where there was moderate overall risk, including [22,26,34,41] since there were concerns related to target population, sampling frame, and sampling method. The most common domain-level limitation in the included cross-sectional studies was non-response or missing data, which was rated as moderate in [18,20,22,23,24,25,27,31,34,39,40,41,42]. Concerning the validity of BP measurement, most included cross-sectional studies had low risk of bias, but there were some moderate concerns, including [38,39,40]. Regarding the only longitudinal study evaluated using the Newcastle&amp;ndash;Ottawa Scale (Figure 3), moderate overall risk was found in [28].
&amp;nbsp;

&amp;nbsp;
Figure 2: Bias Assessment Using AXIS Tool
&amp;nbsp;

&amp;nbsp;
Figure 3: Bias Assessment Using NOS Tool
&amp;nbsp;
Demographic Variables Assessed
The included evidence base had predominantly cross-sectional nature [18-27, 29-42], with one longitudinal cohort component [28], and involved African [18-20], Middle Eastern [22, 23], South Asian [21,32-37], East Asian [38], Latin American [26-29], European [24, 25, 39], and multicountry settings [39-42] (Table 2). The sample size was heterogeneous, ranging from 286 individuals in Colombia [26] to 825,954 surveyed participants in India [37]. The age structure varied from younger adult samples aged 15-49 years [37] and 15-64 years [23] to older-adult samples aged &amp;ge;50 years [28, 40] and &amp;ge;60 years [27]. The female predominance was found in several samples, such as Sudan [19], England [25], Brazil [27], Malaysia [30], Indonesia [31], Nepal [32], India [36], and PURE countries [42], while the male predominance prevailed in Lebanon [22] and Peru [29].
&amp;nbsp;
Table 2: Demographic Variables of the Included Studies




Author


Year


Country / region


Study design


Sample size


Mean age (years)


Male:Female ratio




Cham et al. [18]


2018


Gambia


National WHO STEPS cross-sectional survey


3,573


38.3 +/- 10.9


1,633:1,940




Pengpid et al. [19]


2022


Sudan


National STEPS cross-sectional survey


7,226


Median 37 (IQR 27-49)


2,669:4,557




Odili et al. [20]


2020


Nigeria


Nationwide cross-sectional survey


4,192


46.7


1,815:2,377




Rannan-Eliya et al. [21]


2025


Sri Lanka


Nationally representative cross-sectional baseline analysis


6,342


49.9 +/- 17.2


3,107:3,235




Matar et al. [22]


2015


Lebanon


Community-based cross-sectional survey


1,697


42.9 +/- 15.8


954:743




Saeed et al. [23]


2011


Saudi Arabia


National WHO STEPS community cross-sectional survey


4,758


15-64 age range; mean not stated


2,340:2,418




Uhernik et al. [24]


2023


Croatia


European Health Interview Survey cross-sectional analysis


5,461


&amp;gt;=15 age range; mean not stated


2,368:3,088




Campbell et al. [25]


2023


England


Pooled national cross-sectional cohort analysis


21,476


&amp;gt;=16 age range; mean not stated


9,485:11,991




Salazar et al. [26]


2023


Colombia


Population-based cross-sectional study


286


50.2 +/- 18.8


123:163




Oliveira et al. [27]


2019


Brazil


SABE population-based cross-sectional study


1,233


&amp;gt;=60 age range; mean not stated


approx. 486:747




Dieteren et al. [28]


2021


Mexico


Longitudinal cohort analysis


945


70.7 +/- 8.0


422:523




Guerrero-Diaz et al. [29]


2021


Peru


National survey-based cross-sectional analysis


3,697 hypertensive adults


56.7 +/- 15.5


2,157:1,540




Abdul Rahim et al. [30]


2025


Malaysia


National ageing-survey cross-sectional analysis


2,838


Median 57 (IQR 50-65)


1,306:1,532




Mahwati et al. [31]


2022


Indonesia


Cross-sectional IFLS analysis


5,914 hypertensive adults


approx. 57.4


2,504:3,410




Mehata et al. [32]


2018


Nepal


National population-based cross-sectional survey


13,598


15-69 age range; mean not stated


5,593:8,005




Hasan et al. [33]


2020


Nepal


National population-based cross-sectional analysis


3,334 hypertensive adults


49.8 (95% CI 49.1-50.5)


49.5%:50.5%




Khanam et al. [34]


2015


Bangladesh


Rural community-based cross-sectional study


6,094


44.2


3,061:3,033




Ahmed et al. [35]


2019


Bangladesh


National survey-based cross-sectional analysis


1,685 hypertensive adults from 8,835 participants


&amp;gt;=35 age range; mean not stated


38.3%:61.7%




Mohanty et al. [36]


2021


India


Nationally representative cross-sectional LASI analysis


64,427


Median 57 (IQR 49-65)


27,154:37,273




Das et al. [37]


2025


India


NFHS-5 secondary cross-sectional analysis


825,954 surveyed; 144,500 hypertensive subsample


15-49 age range; mean not stated


101,839:724,115




Zhang et al. [38]


2023


China


Six-round national repeated cross-sectional survey


642,523


18-69 age range; mean not stated


Sex distribution not tabulated in extracted main text




Joffres et al. [39]


2013


England, USA, Canada


Comparative national cross-sectional survey analysis


20,361


20-79 age range; mean not stated


Country-specific sex distribution




Lloyd-Sherlock et al. [40]


2014


China, Ghana, India, Mexico, Russia, South Africa


WHO SAGE national cross-sectional analysis


35,125


&amp;gt;=50 age range; mean not stated


48.0%:52.0%




Irazola et al. [41]


2016


Nine LMICs


Multicountry population-based cross-sectional analysis


33,660


35-74 age range; mean not stated


15,562:18,098




Chow et al. [42] Reviewer revision: Verify age, sex, sample size and survey-population descriptors against each original study; some entries contain approximate or inconsistent totals.


2013


17 countries


PURE baseline cross-sectional analysis


142,042


50.58 +/- 9.7


59,435:82,607




&amp;nbsp;
Methodological Domains Assessed
In terms of the methodological assessment (Table 3), the majority of studies used national or population-based sampling frame [18-21, 23-25, 29-33, 35-40, 42], while some of them used community-based or municipal sampling frame [22, 26, 34, 41]. Blood pressure measurement was done based on the standardized criteria, such as two measurements [21, 24, 29, 42], three measurements [18, 19, 23, 25-28, 31, 33, 35-38, 40], five measurements [20], and six measurements in Canada [39]. Hypertension was defined by SBP &amp;ge;140 mmHg and/or DBP &amp;ge;90 mmHg [18-42], with an addition of medications intake or previous diagnosis in several cascade-based studies [18, 20-23, 27, 28, 32, 33, 36, 38-42]. Adjustment for potential confounders was done by means of age [20-22, 24, 27-29, 32-36, 38-42], sex [20-22, 24, 27-29, 32-36, 38-42], BMI [20, 22, 24, 26-29, 32-36, 38, 40, 41], socioeconomic status [21, 22, 24, 27-29, 31, 33, 35, 36, 40-42], and place of residence/region [18-21, 24, 25, 28, 29, 32, 33, 35-38, 40-42].
&amp;nbsp;
Table 3: Methodological Domains of the Included Studies




Author


Data platform/source


Population frame


Selection architecture


Recruitment coverage


BP acquisition


Hypertension rule


Case-status classification


Adjustment domains




Cham et al. [18]


WHO STEPS 2010


2003 census/EAs


Multistage stratified random


National household


3 seated automated readings; mean 2nd-3rd


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or self-report


Diagnosed vs undiagnosed HTN; treatment/control assessed


Demographic, residence, lifestyle, obesity




Pengpid et al. [19]


Sudan STEPS 2016


National household survey


Multistage stratified


National household


3 Omron readings after 15-min rest; mean last 2


SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP + no doctor/health-worker diagnosis


Predisposing, enabling, need factors




Odili et al. [20]


REMAH/Nigerian national survey


Six geopolitical zones


Multistage community sampling


Rural and urban communities


5 auscultatory readings; mean of 5


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or treatment


Awareness = previous health-worker diagnosis


Age, sex, BMI, residence, zone




Rannan-Eliya et al. [21]


SLHAS Wave 1


National adult population


Stratified multistage probability


National non-institutionalized


2 Omron readings, 10-min interval; mean of 2


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or antihypertensive medication with diagnosis


Extended care cascade: screened, diagnosis, awareness, treatment, adherence, control


Sex, age, ethnicity, SES, province, diabetes, provider




Matar et al. [22]


Lebanon field survey


Public gathering venues


Multisite community recruitment


Six provinces


2 automated readings after rest; 3rd if discordant


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or medication


Awareness = doctor/healthcare professional told or medication


SES, CVD risks, BMI, smoking, alcohol




Saeed et al. [23]


Saudi WHO STEPS 2005


20 health regions/PHCC catchments


Multistage stratified cluster


National community


3 digital readings, 5-min intervals


Mean BP &amp;gt;=140/90 or known HTN


Awareness = health-professional confirmed HTN


Demographic, lifestyle, biochemical variables




Uhernik et al. [24]


Croatian EHIS wave 3


3,600 dwellings


Two-stage random address sampling


National household


2 BP measures &amp;gt;=20 min apart; mean used


Mean SBP &amp;gt;=140 and/or DBP &amp;gt;=90


No high BP in past 12 months + raised measured BP


Demographic, SES, BMI, healthcare use




Campbell et al. [25]


Health Survey for England 2015-2019


Private households


Multistage stratified probability


National household


3 readings; mean 2nd-3rd


Self-reported diagnosis or BP &amp;gt;=140/90


BP &amp;gt;=140/90 + no self-reported diagnosis


Ethnicity, region, rurality, education, NS-SEC, BMI, smoking




Salazar et al. [26]


Sabaneta population survey


Municipal households


Stratified and systematic selection


Colombian municipality


3 readings after 15-min rest, 5-min intervals


SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP + no prior diagnosis or medication


Lifestyle, anthropometry, sedentary status, comorbidity




Oliveira et al. [27]


SABE 2010


Sao Paulo older population


Probabilistic sample


Urban older adults


3 BP readings; first excluded; mean last 2


BP &amp;gt;=140/90, self-report, or antihypertensive use


Diagnosed, undiagnosed, controlled, uncontrolled


SES, healthcare access, health status, CNCDs




Dieteren et al. [28]


WHO SAGE Mexico Waves 1 and 2


National older-adult sample


Cluster/probability sampling


National ageing cohort


3 wrist-monitor readings; mean last 2


Mean SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or diagnosis


Persistent undiagnosed, untreated, uncontrolled over 5 years


Sex, age, cohabitation, rurality, wealth, insurance, BMI




Guerrero-Diaz et al. [29]


ENDES 2019


National demographic-health survey


Complex national survey sampling


National urban/rural


2 readings; 5-min rest then 2-min interval


Mean SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP + no prior professional diagnosis


Demographic, SES, insurance, BMI, diabetes, altitude




Abdul Rahim et al. [30]


MARS Wave 1


2010 census enumeration blocks


Multistage random sampling


National ageing survey


Omron HEM-7120; average of 3 readings


Average SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP + no doctor diagnosis


Predisposing, enabling, need factors




Mahwati et al. [31]


IFLS 2014-2015


Indonesian adults with BP and diagnosis data


IFLS household-based survey; analytic hypertensive subset


Nationally representative IFLS provinces


Omron HEM-7203; mean of 3 BP readings


Mean SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Hypertensive + no professional diagnosis + no prescription


Education, PCE, residence, health access, symptoms, disability, health status




Mehata et al. [32]


NDHS 2016


Nepalese men and women


Stratified multistage cluster sampling


National urban/rural


Home BP measurement; NDHS biomarker module


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or medication


Awareness, treatment, controlled cascade


Age, sex, education, marital status, BMI, wealth, province, residence




Hasan et al. [33]


NDHS 2016


Hypertensive Nepalese adults


Two/three-stage multistage survey design


National household sample


UA-767F/FAC; 3 readings; mean last 2


SBP &amp;gt;=140 and/or DBP &amp;gt;=90, prior diagnosis, or medication


Raised BP, never diagnosed, never treated


Age, sex, BMI, wealth, province, residence, ecological zone, tobacco/alcohol/caffeine




Khanam et al. [34]


Rural HDSS sites, 2005


Rural Bangladeshi adults


Surveillance-site community sampling


Matlab, Abhoynagar, Mirsarai


WHO STEPS BP protocol


Measured hypertension by standard BP threshold


No self-reported HTN but measured HTN; treated but BP high for uncontrolled


Age, sex, education, wealth, smoking, chewing tobacco, BMI, physical activity




Ahmed et al. [35]


BDHS 2011


Bangladeshi adults with measured BP


National two-stage cluster sampling


National urban/rural


LIFE SOURCE UA-767 Plus; 3 readings; mean last 2


SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP, never diagnosed, never treated


Age, sex, education, BMI, wealth, division, residence




Mohanty et al. [36]


LASI 2017-2018


Adults &amp;gt;=45 and spouses


National state-level household sample


All Indian states except Sikkim


Omron HEM-7121; 3 readings; mean last 2


BP &amp;gt;=140/90 or self-reported diagnosis with medication/ diet/salt restriction


Aware, treated, controlled cascade


MPCE, education, age, sex, residence, caste, religion, insurance, state




Das et al. [37]


NFHS-5 2019-2021


Indian men/women with biomarker BP data


Stratified two-stage national DHS sampling


National rural/urban; all states/UTs


Omron BP monitor; 3 readings; mean 2nd-3rd


Mean SBP &amp;gt;=140 and/or DBP &amp;gt;=90


Raised BP + no current HTN + no prior diagnosis + no medication


Sex-stratified rural/urban models; SES, caste, education, occupation, BMI, behaviours




Zhang et al. [38]


CCDRFS 2004-2018


Chinese community adults


Stratified clustered multistage national sampling


Mainland China; 6 survey rounds


3 readings; mercury in 2004, Omron from 2007; mean last 2


BP &amp;gt;=140/90 or antihypertensive drugs


Awareness, treatment, control; undiagnosed derivable from non-awareness


Sex, age, residence, education, region, BMI, central obesity




Joffres et al. [39]


HSE/NHANES/CHMS


Non-institutionalized adults


Country-specific multistage national surveys


England, USA, Canada


England/USA: 3 readings; Canada: 6 readings


Mean BP &amp;gt;=140/90 or BP medication


Aware, treated, controlled, treated-uncontrolled


Sex, age, country, mortality correlation




Lloyd-Sherlock et al. [40]


WHO SAGE


Older adults in six LMICs


Multistage stratified random cluster sampling


National household surveys


Boso Medistar wrist device; 3 readings; mean last 2


Mean BP &amp;gt;=140/90 or antihypertensive use


Aware, treated, controlled, treatment efficacy


Age, sex, BMI, education, wealth, insurance, urban/rural




Irazola et al. [41]


NHLBI/UHG COE network


Adults from selected LMIC communities


Random population-based samples across 7 studies


9 LMICs; Africa, Asia, South America


&amp;gt;=2 seated readings after &amp;gt;=5-min rest; site-specific devices


SBP &amp;gt;=140 and/or DBP &amp;gt;=90 or medication


Awareness, treatment among aware/all HTN, control among treated/all HTN


Age, sex, education, BMI, central obesity, site




Chow et al. [42] Reviewer revision: Verify source definitions, BP measurement protocols and exact numerator/denominator for each study before pooling.


PURE baseline


Adults from urban/rural communities


Community household sampling


628 communities in 17 countries


Omron HEM-757; mean of 2 readings


Self-reported treated HTN or BP &amp;gt;=140/90


Awareness, treatment, control; undiagnosed derivable


Country income, sex, age, urban/rural, education




&amp;nbsp;
Outcome associated observations
The results of the outcome assessment reveal that undiagnosed hypertension was prevalent in several LMICs (Table 4): Gambia 79.0% [18]; Sudan 79.2% [19]; Peru 67.2% [29]; Bangladesh 59.9% [35]; Indonesia 56.2% [31]; Malaysia 55.9% [30]; Saudi Arabia 55.3% [23]; Nepal 50.4% [33]; and PURE countries 53.5% [42]. Awareness was relatively low in Nepal 38.0% [32]; China 38.3% [38]; Saudi Arabia 44.7% [23]; PURE countries 46.5% [42]; and WHO SAGE countries 48.3% [40]. Treatment was still not optimal in Nepal 18.0% [32]; China 34.6% [38]; Saudi Arabia 71.8% in aware adults [23]; India 50.8% [36]; and PURE countries 40.6% in all hypertensive [42]. Control was poor across the studied populations, including Gambia 4.0% [18]; Nepal approximately 9.4% [32]; China 12.0% [38]; PURE countries 13.2% [42]; Sri Lanka 20.0% [21]; India 28.8% [36]; and WHO SAGE countries 10.2% [40]. Male gender was linked to the higher hidden burden of hypertension in Sudan [19], Saudi Arabia [23], Croatia [24], Peru [29], Malaysia [30], Indonesia [31], Nepal [33], Bangladesh [35], and India [37], while older age generally increased hypertension burden but reduced underdiagnosis in Peru [29], Bangladesh [35], and Nepal [33].
&amp;nbsp;
Table 4: Outcome-Associated Variables of the Included Studies




Author


Outcome extraction class


Main denominator


HTN burden / analytic base


Hidden hypertension estimate


Known / aware estimate


Largest diagnosis-control gap available


Gender-related signal


Age-related signal


Key adjusted / stratified signal


Overall inference drawn




Cham et al. [18]


Diagnosed/undiagnosed HTN + cascade


All hypertensives; treated self-reported HTN for control


Total HTN 29.0%; raised BP 27.0%


79.0% of HTN; men 86.0%, women 71.0%


21.0% of HTN; self-reported HTN n=314


Only 4.0% of all HTN controlled; 76.0% of treated uncontrolled


Men had greater hidden burden


HTN increased with age


Rural LGA: men AOR 3.2; women AOR 2.5; obesity/smoking/inactivity relevant


National burden dominated by undetected HTN and negligible population-level control




Pengpid et al. [19]


Direct undiagnosed HTN


Adults 18-69 with complete BP and survey data


Total HTN 33.1% (n=2,747)


26.2% of sample; 79.2% of HTN (n=2,057)


Diagnosed HTN 6.9%; 20.8% of HTN


Diagnosis gap = 79.2% of all HTN


Male sex: undiagnosed vs diagnosed aOR 2.22


50-69 yr: aRR 2.49 vs no HTN; aOR 0.31 vs diagnosed


Obesity aRR 2.51; diabetes aRR 1.59; cholesterol aRR 1.48; health advice aRR 0.79


Around 8/10 hypertensive adults were undiagnosed, with health-contact variables protective




Odili et al. [20]


National HTN care cascade


All hypertensives from nationwide survey


Age-standardized HTN 38.1%


Non-awareness approx. 40.8%


Awareness approx. 59.2%


Control 12.4% of HTN; 65.4% of treated uncontrolled


Women more aware than men; control similar


HTN increased from 6.8% (&amp;lt;30 yr) to 63.0% (&amp;gt;=70 yr)


Urban treatment 40.9% vs rural 30.8%; urban awareness 62.2% vs rural 56.6%


High national prevalence with major loss between awareness, treatment, and control




Rannan-Eliya et al. [21]


Extended diagnosis-treatment-control cascade


All hypertensive adults in SLHAS


HTN 27.6%


Non-diagnosis 47.2%; non-awareness 50.4%


Diagnosed 52.8%; aware 49.6%


Only 20.0% of all HTN controlled; 80.0% not controlled


Females had better screening, diagnosis, treatment, and control


Cascade improved with age but control plateaued at older ages


Female diagnosis aOR 1.72; female screening aOR 1.92; diabetes/BMI improved diagnosis


Largest losses occurred at diagnosis and after treatment, despite broad screening exposure




Matar et al. [22]


Prevalence-awareness-treatment-control cascade


Adults with measured BP in community survey


HTN 36.9% crude; 35.9% age-sex adjusted


Non-awareness 47.0%


Awareness 53.0%


Overall control 27.0%; treated-control 54.2%; treated-uncontrolled 45.8%


Men had lower treated control: 48.9% vs women 62.3%


HTN nearly 75.0% in &amp;gt;=65 yr


Age, male sex, BMI, diabetes, hyperlipidemia predicted HTN


Awareness was the principal bottleneck; treated control was moderate but overall control remained low




Saeed et al. [23]


National STEPS HTN cascade


Saudi adults with measured BP


HTN 25.5% (n=1,213)


55.3% of HTN newly detected (n=671)


Awareness 44.7% (n=542)


37.0% of treated controlled; 63.0% of treated uncontrolled


Male HTN 27.1% vs female 23.9%; awareness male 37.3%, female 53.3%


HTN increased from 8.8% (15-24 yr) to 57.5% (55-64 yr)


Male sex, urbanization, low education, inactivity, obesity, diabetes, cholesterol predicted HTN


More than half of hypertensive adults were newly detected, with suboptimal treatment control




Uhernik et al. [24]


Direct undiagnosed HTN


EHIS participants with measured BP


Total HTN 44.3%; diagnosed 37.2%, undiagnosed 7.1%


7.1% population; approx. 16.0% of HTN


Approx. 84.0% of HTN diagnosed


Diagnosis gap concentrated in healthcare non-users


Undiagnosed: male 10.0% vs female 4.9%


Undiagnosed highest around 45-74 yr


Women had lower OR; older age, BMI, no family-doctor visit associated


Undiagnosed HTN was lower than in LMICs but clustered in men and healthcare non-users




Campbell et al. [25]


Direct undiagnosed HTN


Adults with total HTN in HSE 2015-2019


HTN: men 34.3%, women 29.7%; hypertensive n=7,997


Men 30.7%; women 27.6% of HTN


Men 69.3%; women 72.4% diagnosed/known


Hidden burden highest in low-risk younger groups


Men slightly more undiagnosed than women


Highest undiagnosed: men 16-24 yr 66.2%; women 25-34 yr 44.0%


Rural men 41.9% vs urban 32.3%; lower BMI and better self-rated health increased underdiagnosis


High-income setting still had substantial hidden HTN, especially among younger/low-risk profiles




Salazar et al. [26]


Direct undiagnosed HTN


Normotensive vs diagnosed vs undiagnosed adults


HTN 38.5%


50.9% of HTN (n=56)


49.1% of HTN diagnosed (n=54)


Diagnosis gap = about half of all HTN


Undiagnosed similar by sex; female 18.4%, male 21.1% of total sample


&amp;gt;60 yr prominent among HTN; RRR 0.68 reported for undiagnosed category


Elementary education RRR 1.75; physical activity RRR 1.52; no comorbidity RRR 1.42; obesity RRR 2.25


Half of hypertensive adults were undiagnosed despite measurable cardiometabolic clustering




Oliveira et al. [27]


Diagnosed, undiagnosed, controlled, uncontrolled HTN


Older adults in SABE 2010


HTN 79.5%


9.1% population; approx. 11.4% of HTN


Diagnosed/known approx. 88.6% of HTN


Uncontrolled 36.0% population; 51.0% of hypertensive condition


Female sex reduced uncontrolled HTN OR 0.61


Diagnosed HTN higher at 70-79 yr OR 2.02 and &amp;gt;=80 yr OR 2.73


Undiagnosed: nonwhite OR 1.89; uninsured OR 1.77; overweight OR 2.38; &amp;gt;=1 CNCD OR 0.28


In elderly adults, uncontrolled HTN exceeded undiagnosed HTN as the dominant residual burden




Dieteren et al. [28]


Persistent undiagnosed, untreated, uncontrolled HTN


Mexicans aged 50+ observed in two SAGE waves


HTN 64.4% at Wave 2; persistent HTN 51.1%


Persistent undiagnosed 11.3%; Wave 2 undiagnosed 22.2%


Wave 2 diagnosed approx. 77.8% of HTN


Persistent uncontrolled 34.7%; persistent untreated 15.3%


Men more likely to have persistent care gaps


Older cohort; HTN burden high across 50+ population


Singles, rural dwellers, uninsured, overweight groups had persistent gaps


Longitudinal evidence showed durable failures in diagnosis, treatment, and control




Guerrero-Diaz et al. [29]


Direct undiagnosed HTN


Adults with BP-compatible HTN in ENDES 2019


Hypertensive analytic base n=3,697


67.2% of HTN (n=2,549)


32.8% diagnosed (n=1,148)


Diagnosis gap = two-thirds of hypertensive adults


Men 74.7% vs women 55.7% undiagnosed


18-29 yr 94.5% vs &amp;gt;=70 yr 47.5% undiagnosed


Male aPR 1.15; poorest aPR 1.18; coast aPR 1.17; &amp;gt;=3000 m aPR 1.20; diabetes aPR 0.55


Undiagnosed HTN was very high and socioeconomically patterned toward poorer groups




Abdul Rahim et al. [30]


Direct undiagnosed HTN


Middle-aged/older adults with elevated BP


Elevated-BP analytic base n=2,838


55.9% overall; middle-aged 63.8%, older 45.5%


44.1% diagnosed; middle-aged 36.2%, older 54.5%


Diagnosis gap highest in middle-aged adults


Middle-aged men 69.3%; older men 53.8% undiagnosed


Middle-aged &amp;gt; older for underdiagnosis


Medical check-up lowered odds: middle aOR 0.28, older aOR 0.26; diabetes lowered odds: 0.39/0.26


Health-service utilization strongly explained hidden HTN in ageing Malaysians




Mahwati et al. [31]


Direct undiagnosed HTN


Hypertensive Indonesian adults in IFLS


Hypertensive analytic base n=5,914


56.2% of HTN (n=3,322)


43.8% diagnosed (n=2,592)


Diagnosis gap = 56.2% of HTN


Male 64.5% vs female 50.0% undiagnosed


Age distribution similar between diagnosed and undiagnosed groups


Primary/lower education OR 1.60; low PCE OR 1.28; no morning headache OR 1.97; healthy status OR 2.05


Hidden HTN predominated among poorer, less educated, and apparently healthier adults




Mehata et al. [32]


National HTN cascade


All hypertensive adults in NDHS


HTN 18.0%; men 22.0%, women 15.0%


Non-awareness 62.0%


Awareness 38.0%


Treatment 18.0%; controlled among treated 52.0%; approx. 90.6% of all HTN not controlled


Men had higher prevalence and weaker care cascade


HTN 34.0% in 45-69 yr


Age 45-69 AOR 7.26; male AOR 1.56; overweight AOR 3.57; obesity AOR 5.19


National Nepal data showed low awareness and treatment despite measurable HTN burden




Hasan et al. [33]


Direct undiagnosed HTN


Hypertensive Nepalese adults


Hypertensive analytic base n=3,334


50.4% of HTN


49.6% diagnosed/known


Diagnosis gap = 50.4%; poor-rich gap 24.6 pp


Male 54.2% vs female 46.7% undiagnosed


Undiagnosed decreased with age; &amp;gt;=65 yr AOR 0.65


Male AOR 1.29; overweight/obese AOR 0.80; concentration index -0.18


Undiagnosed HTN clustered among young, male, poorer, and lower-risk phenotypes




Khanam et al. [34]


Direct undiagnosed + uncontrolled HTN


Rural adults; treated self-reported HTN for uncontrolled


Self-reported HTN 14.9%; undiagnosed HTN 11.1% population-level


Undiagnosed HTN 11.1%; &amp;gt;=60 yr 22.7%


Self-reported HTN 14.9%; 43.0% of self-reported treated


54.9% of treated HTN uncontrolled


Undiagnosed: men 9.7%, women 12.6%


Undiagnosed 5.5% (25-39 yr) to 22.7% (&amp;gt;=60 yr); uncontrolled 34.5% to 67.9%


Increasing age and BMI predicted undiagnosed; age and wealth predicted uncontrolled


Rural Bangladesh had simultaneous diagnostic and treatment-control failures




Ahmed et al. [35]


Direct undiagnosed HTN + inequality


Hypertensive adults in BDHS


HTN n=1,685 from 8,835; approx. 19.1%


59.9% of HTN (n=978)


40.1% diagnosed/known


Diagnosis gap concentrated in poorer groups: poorest 69.7% vs richest 50.8%


Male 66.9% vs female 55.5% undiagnosed


Age &amp;gt;=50 less likely undiagnosed; 50-64 AOR 0.53; &amp;gt;=65 AOR 0.49


Female AOR 0.68; poorest AOR 1.86; concentration index -0.07


Undiagnosed HTN was concentrated among poor, male, and less educated adults




Mohanty et al. [36]


National HTN cascade


Adults &amp;gt;=45 and spouses with HTN


HTN 41.9%


Non-awareness 45.6%; undiagnosed population prevalence 19.1%


Awareness 54.4%


Treatment 50.8%; control 28.8%; uncontrolled 71.2%


Males had lower awareness, treatment, and control


Older adults had higher HTN burden; younger were less diagnosed/treated


Richest vs poorest: awareness +8.5 pp, treatment +8.9 pp, control +7.1 pp; ATC pro-rich


Older Indian adults had high HTN with incomplete and inequitable cascade performance




Das et al. [37]


Direct undiagnosed HTN


Working-age hypertensive adults in NFHS-5


Undiagnosed prevalence: men 11.7%, women 7.2%; HTN subsample n=144,500


Among HTN: men 66.3%, women 41.4%


Known HTN: men 33.7%, women 58.6%


Diagnosis gap substantially larger in men


Men had markedly higher underdiagnosis


Working-age analysis; younger/low-contact profiles emphasized


Urban-rural predictors differed; education, empowerment, and screening access were emphasized


Working-age India showed a major sex gap in hidden HTN, especially among men




Zhang et al. [38]


National repeated HTN cascade


Adults 18-69 with measured BP across 6 rounds


Standardized HTN 24.7% in 2018; crude 38.1%


Non-awareness 61.7% in 2018


Awareness 38.3% in 2018


Treatment 34.6%; control 12.0%; inadequate control 88.0%; 240M/274M uncontrolled


Prevalence decline after 2010 greater among women than men


Adult 18-69 trend across 2004-2018


Rural-control gap persisted; low education affected women&amp;rsquo;s HTN prevalence


China improved modestly, but population-level diagnosis and control remained inadequate




Joffres et al. [39]


Three-country HTN cascade comparison


Hypertensive adults aged 20-79 in national surveys


HTN: England 30.0%, USA 29.1%, Canada 19.5%


Non-awareness: England 34.7%, USA 18.9%, Canada 16.6%


Awareness: England 65.3%, USA 81.1%, Canada 83.4%


Control: England 27.3%, USA 52.8%, Canada 65.8%; uncontrolled inverse


Women generally showed better cascade patterns


Older age had higher prevalence but more diagnosis/treatment


Country-level system differences dominated cascade performance


Canada had the strongest cascade, England the weakest, despite all being high-income settings




Lloyd-Sherlock et al. [40]


WHO SAGE older-adult cascade


Adults &amp;gt;=50 with measured BP in six LMICs


Overall HTN 52.9%; range 32.3% India to 77.9% South Africa


Non-awareness 51.7%


Awareness 48.3%; range 23.3% Ghana to 72.1% Russia


Control 10.2%; uncontrolled 89.8%; treatment efficacy 26.3%


Women had higher awareness and better control


HTN prevalence increased with age


Awareness linked to older age, female sex, overweight/obesity; control linked to age, female sex, wealth


Older LMIC adults had very high HTN and extremely weak control




Irazola et al. [41]


Multicountry LMIC HTN cascade


Adults 35-74 from selected LMIC communities


HTN range 19.2% Peru to 54.9% South Africa


Non-awareness range 31.0%-66.5%


Awareness range 33.5% India to 69.0% Peru


Control among all HTN 5.3% China to 45.9% Peru


Women generally had better cascade in several settings


Age-standardized 35-74 analysis


Site, education, age, sex, and cardiometabolic profiles shaped variation


LMIC communities showed heterogeneous prevalence but consistently poor control in several regions




Chow et al. [42]
Reviewer revision: Verify all study-specific outcome percentages, denominators and any reconstructed counts against source publications.


PURE multinational HTN cascade


Adults 35-70 with HTN across 17 countries


HTN 40.8% (n=57,840)


Non-awareness 53.5%


Awareness 46.5%


Treatment 40.6% of all HTN; control 13.2% of all HTN; 86.8% not controlled


Women had higher awareness, treatment, and control than men


Older adults had higher prevalence and treatment exposure


LIC and rural LMIC settings had lower awareness/treatment/control; low education worsened LIC cascade


PURE provided the strongest multicountry evidence of global diagnosis and control gaps




Outcome-associated variables of the included studies (Abbreviations: AOR: Adjusted Odds Ratio, aOR: Adjusted Odds Ratio, aPR: Adjusted Prevalence Ratio, aRR: Adjusted Risk Ratio, BP: Blood Pressure, CI: Confidence Interval, CNCD: Chronic Noncommunicable Disease, DBP: Diastolic Blood Pressure, HTN: Hypertension, IQR: Interquartile Range, LMICs: Low- And Middle-Income Countries, OR: Odds Ratio, PCE: Per-Capita Expenditure, SBP: Systolic Blood Pressure, SES: Socioeconomic Status
&amp;nbsp;
Meta-Analysis Observations
Pool 1: Undiagnosed Hypertension: A total of 24 study arms contributed to the undiagnosed hypertension meta-analysis (Figures 4 and 5 respectively). The pooled percentage of undiagnosed hypertension amongst hypertensive participants was 46.4% (95 CI: 42.8 to 50.1%). There was marked heterogeneity (Q = 7960.28, df = 23, I2 = 99.7%, tau2 = 0.1327), which showed significant differences across settings. Nevertheless, the pooled value revealed that close to half of hypertensive patients were still undiagnosed and remained ignorant of their hypertensive condition.
&amp;nbsp;

&amp;nbsp;
Figure 4: Pool 1: Undiagnosed Hypertension among Hypertensive Participants
&amp;nbsp;

&amp;nbsp;
Figure 5: Pool 2A: Uncontrolled Hypertension among Treated Hypertensive Participants
&amp;nbsp;
Pool 2: Uncontrolled Hypertension
For the uncontrolled hypertension amongst treated hypertensive participants, there were 10 study arms (Figure 6). The pooled proportion was 49.6% (95 CI: 37.2 to 62.1%), and it had substantial heterogeneity (Q = 1733.35, df = 9, I2 = 99.5%, tau2 = 0.6625). This was an indication that about half of the treated hypertensive participants had not attained blood pressure control. For the uncontrolled hypertension amongst all hypertensive participants, a total of 13 study arms contributed to the analysis (Figure 7). The pooled proportion was 78.7% (95 CI: 71.2 to 84.6%), and it had substantial heterogeneity (Q = 8229.59, df = 12, I2 = 99.9%, tau2 = 0.5288). This result reflected the cumulative cascade failures of being undiagnosed, diagnosed but untreated, and treated but uncontrolled.
&amp;nbsp;

&amp;nbsp;
Figure 6: Pool 2B: Uncontrolled Hypertension among All Hypertensive Participants
&amp;nbsp;

&amp;nbsp;
Figure 7: Pool 3A: Awareness / Diagnosis among Hypertensive Participants
&amp;nbsp;
Pool 3: Diagnosis-Treatment-Control Cascade
For the awareness/diagnosis pool, 12 study arms contributed to the analysis (Figures 8 and 9 respectively). The pooled percentage of awareness or diagnosis was 52.5% (95% CI: 47.3 to 57.7%), and it had substantial heterogeneity (Q = 3726.11, df = 11, I2 = 99.7%, tau2 = 0.1331). For the treatment pool, there were 11 study arms and the pooled proportion was 43.5% (95 CI: 37.4 to 49.8%) (Q = 4017.34, df = 10, I2 = 99.8%, tau2 = 0.1823). The control pool had 13 study arms and the pooled proportion was 21.3% (95 CI: 15.4 to 28.8%) (Q = 8229.59, df = 12, I2 = = 99.9%, tau2 = 0.5288).
&amp;nbsp;

&amp;nbsp;
Figure 8: Pool 3B: Treatment among Hypertensive Participants
&amp;nbsp;

&amp;nbsp;
Figure 9: Pool 3C: Blood Pressure Control among Hypertensive Participants
&amp;nbsp;
Publication Bias Assessment
The funnel plot analysis of undiagnosed hypertension included 24 estimates with a pooled proportion of 46.4% (95% CI: 42.8-50.1%) with very high heterogeneity (I&amp;sup2; = 99.7%, &amp;tau;&amp;sup2; = 0.1327). Both Egger&amp;rsquo;s test (intercept = -4.12, p = 0.441) and Begg&amp;rsquo;s test (&amp;tau; = -0.17, p = 0.268) were non-significant, thus, there is no statistical evidence of asymmetry (Figure 10).
&amp;nbsp;

&amp;nbsp;
Figure 10: Funnel Plot for Undiagnosed Hypertension
Points represent study arms, dashed lines represent pseudo 95% limits and dotted lines represent pseudo 99% limits. Asymmetry was interpreted cautiously because global prevalence estimates showed high heterogeneity
&amp;nbsp;
In the case of uncontrolled hypertension among treated participants, there were 10 estimates with a pooled proportion of 49.6% (95% CI: 37.2-62.1%) and substantial heterogeneity (I&amp;sup2; = 99.5%, &amp;tau;&amp;sup2; = 0.6625). Egger&amp;rsquo;s test (intercept = -11.70, p = 0.049) was statistically significant, while Begg&amp;rsquo;s test (&amp;tau; = -0.02, p = 1.000) was not, therefore, there might be a signal of small-study asymmetry (Figure 11).
&amp;nbsp;

&amp;nbsp;
Figure 11: Funnel Plot for Uncontrolled Among Treated
Points represent study arms, dashed lines represent pseudo 95% limits and dotted lines represent pseudo 99% limits. Asymmetry was interpreted cautiously because global prevalence estimates showed high heterogeneity
&amp;nbsp;
For uncontrolled hypertension among all hypertensive participants, there were 13 estimates with a pooled proportion of 78.7% (95% CI: 71.2-84.6%) with very high heterogeneity (I&amp;sup2; = 99.9%, &amp;tau;&amp;sup2; = 0.5288). Both Egger&amp;rsquo;s test (intercept = -9.10, p = 0.449) and Begg&amp;rsquo;s test (&amp;tau; = 0.13, p = 0.590) were non-significant, thus, there was no statistical asymmetry signal (Figure 12).
&amp;nbsp;

&amp;nbsp;
Figure 12: Funnel Plot for Uncontrolled among All Hypertensives
&amp;nbsp;
There were 12 estimates for awareness/diagnosis with a pooled proportion of 52.5% (95% CI: 47.3-57.7%) with high heterogeneity (I&amp;sup2; = 99.7%, &amp;tau;&amp;sup2; = 0.1331). Both Egger&amp;rsquo;s test (intercept = 8.32, p = 0.327) and Begg&amp;rsquo;s test (&amp;tau; = 0.18, p = 0.459) were non-significant, thus, there is no evidence of publication bias (Figure 13).
&amp;nbsp;

&amp;nbsp;
Figure 13: Funnel Plot for Awareness/Diagnosis
Points represent study arms; dashed lines represent pseudo 95% limits and dotted lines represent pseudo 99% limits. Asymmetry was interpreted cautiously because global prevalence estimates showed high heterogeneity
&amp;nbsp;
The treatment estimates consisted of 11, with a pooled proportion of 43.5% (95% CI: 37.4 &amp;ndash; 49.8%) and extremely high heterogeneity (I&amp;sup2; = 99.8%, &amp;tau;&amp;sup2; = 0.1823). The Egger&amp;rsquo;s test (intercept = 3.69, p = 0.697) and Begg&amp;rsquo;s test (&amp;tau; = &amp;minus;0.05, p = 0.879) failed to yield statistically significant results, showing no statistical evidence of funnel-plot asymmetry (Figure 14).
&amp;nbsp;

&amp;nbsp;
Figure 14: Funnel Plot for Treatment
Points represent study arms; dashed lines represent pseudo 95% limits and dotted lines represent pseudo 99% limits. Asymmetry was interpreted cautiously because global prevalence estimates showed high heterogeneity
&amp;nbsp;
In the case of blood pressure management, there were 13 estimates used for the pooled proportion of 21.3% (95% CI: 15.4 to 28.8%) with a very high degree of heterogeneity (I&amp;sup2; = 99.9%, &amp;tau;&amp;sup2; = 0.5288). The Egger&amp;rsquo;s test had an intercept of 9.10 (p = 0.449), and Begg&amp;rsquo;s test had &amp;tau; = &amp;minus;0.13, p = 0.590) which were non-significant, indicating no statistical evidence of publication bias.
&amp;nbsp;
The principal finding is that substantial gaps in hypertension diagnosis and blood pressure control were observed across the included population-based studies. The pooled estimate for undiagnosed hypertension was 46.4%, not more than half, and the pooled estimate for uncontrolled blood pressure among all hypertensive participants was 78.7%. These proportions came from outcome-specific evidence subsets and were accompanied by extreme heterogeneity (I&amp;sup2; approximately 99.5&amp;ndash;99.9%). Accordingly, they should not be interpreted as precise estimates for every country or as sequential outcomes from a single global cohort.
&amp;nbsp;
The six pooled indicators describe different stages and denominators: undiagnosed hypertension among hypertensive participants, uncontrolled hypertension among treated participants, uncontrolled hypertension among all hypertensive participants, awareness/diagnosis among hypertensive participants, treatment among the specified hypertensive denominator, and control among the specified hypertensive denominator. The 46.4% undiagnosed and 52.5% awareness estimates are not exact complements because they were derived from different subsets of studies. Similarly, the 49.6% treated-uncontrolled and 78.7% all-hypertensive-uncontrolled estimates must not be directly compared without accounting for different denominators.
&amp;nbsp;
The narrative synthesis identified study-specific associations of underdiagnosis with sex, age, rural residence, socioeconomic disadvantage, and access to healthcare. These patterns were not quantified in a common adjusted meta-analysis and should not be interpreted as universal independent predictors. Differences in survey design, blood pressure thresholds, and participant characteristics may partly explain variation, but their contribution was not formally established by subgroup or meta-regression analyses.
&amp;nbsp;
The pooled estimate of blood pressure control among all hypertensive participants was 21.3% (95% CI 15.4&amp;ndash;28.8%; I&amp;sup2;=99.9%). Among participants receiving antihypertensive treatment, 49.6% remained uncontrolled (95% CI 37.2&amp;ndash;62.1%; I&amp;sup2;=99.5%). These distinct indicators suggest important gaps in hypertension care across the sampled settings; however, the very high heterogeneity and differences in outcome definitions prevent a single representative estimate for all healthcare systems.
&amp;nbsp;
Comparisons with individual national surveys or previous global analyses require attention to survey year, age eligibility, diagnostic threshold, blood pressure measurement protocol, and denominator. Differences between the pooled estimates and country-specific reports should not automatically be attributed to healthcare-system performance. The added contribution of this review is the parallel synthesis of several hypertension-care indicators with explicit recognition that their contributing study sets differ.
&amp;nbsp;
Population-based screening and follow-up may help address gaps in hypertension detection and management, but this prevalence meta-analysis did not directly evaluate intervention effectiveness. Policy decisions should therefore be informed by local surveillance, clinical guidance, healthcare resources, and evidence from intervention studies. Consistent reporting of blood pressure measurement procedures and care-cascade denominators would make comparisons across settings more informative.
&amp;nbsp;
Possible contributors to uncontrolled blood pressure include incomplete detection, delayed treatment initiation, poor adherence, therapeutic inertia, and insufficient follow-up. However, these mechanisms were not uniformly measured or pooled in the included studies and should be regarded as hypotheses or contextual explanations rather than demonstrated causes of the observed prevalence estimates. The review cannot identify which intervention would yield the largest improvement in control.
&amp;nbsp;
This review has several important limitations. First, the 25 included studies covered selected countries and multinational populations, leaving some regions underrepresented; the evidence is not a geographically representative worldwide sample. Second, extreme heterogeneity (I&amp;sup2;=99.5%&amp;ndash;99.9%) limits the usefulness of a single pooled estimate for any individual country. Third, studies varied in diagnostic thresholds, survey years, sampling methods, blood pressure measurement devices and protocols, age ranges, and the definitions and denominators used for awareness, treatment, and control. Fourth, some numerators were reconstructed from rounded percentages, which may introduce error, particularly for survey-weighted estimates. Fifth, database coverage and the restrictive search structure may have missed relevant studies; grey literature and unretrieved reports could also affect representativeness. Sixth, predominantly cross-sectional evidence cannot establish temporal changes or causal explanations. Finally, nonsignificant funnel-plot tests cannot exclude publication bias, and leave-one-out stability does not resolve extreme heterogeneity. These limitations should guide interpretation of all six pooled outcomes.
&amp;nbsp;
The primary observation from this review is that there are still a number of limitations within the continuum of hypertension care around the world, where more than half of people suffering from this condition had not been diagnosed and even fewer had achieved blood pressure control. This was very important since it is not due to difficult cases that cannot be controlled but rather to preventable problems at all stages from screening through to treatment and maintenance. For this reason, in the future, public health policies should focus on BP screening within the whole population, standardization of procedures, linkage to general practitioners, adherence to treatment, and monitoring.
&amp;nbsp;
The assessed findings in this meta-analysis suggested that failure in hypertension care was distributed throughout the entire diagnostic and control phases. Undiagnosed hypertension was estimated to be 46.4% (95% confidence interval: 42.8-50.1%), and uncontrolled hypertension in all participants with hypertension was 78.7% (95% confidence interval: 71.2-84.6%). Such results implied that global burden of hypertension consisted of not only its prevalence rate, but also of insufficient diagnostics and lack of control. This was clinically relevant because hypertension has still been one of the main determinants of cardiovascular and renal pathology [1]. On the other hand, resistant hypertension constituted a narrow clinical subpopulation within the wide group of uncontrolled hypertension [2].
&amp;nbsp;
This systematic review and meta-analysis identified substantial gaps in hypertension diagnosis and control across the included population-based studies. Approximately 46% of hypertensive participants were undiagnosed in one evidence subset, while approximately 79% had uncontrolled blood pressure among all hypertensive participants in a separate subset. These figures are not directly complementary or universally representative estimates, and the very high between-study heterogeneity substantially limits generalization. The awareness, treatment, and control estimates likewise reflect different study subsets and must not be interpreted as sequential stages of one unified cohort. Better harmonization of hypertension definitions, standardized blood pressure measurement, representative population surveillance, and consistent reporting of outcome denominators are needed to support more reliable comparisons and locally appropriate prevention strategies.
&amp;nbsp;
Control failure was even more prominent compared to diagnostic failure. Blood pressure control in all participants with hypertension pooled only to 21.3% (95% confidence interval: 15.4-28.8%), and uncontrolled hypertension in treated patients was 49.6% (95% confidence interval: 37.2-62.1%). This implied that treatment per se could not guarantee sufficient reduction in blood pressure. Poor control had been known in dialysis-related and resistant hypertension populations [7,8]. Prolonged uncontrolled blood pressure has also been linked to increased vascular, renal, cerebrovascular, and cognitive risks [9]. All this suggested that the need of stepwise treatment adjustment, standardized blood pressure measurements, and BP control programs was obvious [10-12].
&amp;nbsp;
As compared to the general literature on hypertension, the estimates of pooled cascade suggested weaker performance of the global healthcare system compared to organized healthcare settings. Complex phenotypes of blood pressure in diabetic and chronic disease patients had needed ongoing diagnosis and treatment [43,44]. National estimates of Spain had demonstrated higher rates of diagnosis and treatment, where about 68% of subjects had been diagnosed with hypertension and 57% had received treatment [45], while this review had revealed pooled awareness/diagnosis of 52.5% and treatment of 43.5%. Such a difference implied that the estimates of global burden were lower due to worse screening, treatment accessibility, and follow-up.
&amp;nbsp;
Table 5: Leave-One-Out Sensitivity Analysis of Pooled Estimates for Hypertension Indicators




Meta-analysis pool


Main pooled estimate (%)


Leave-one-out pooled range (%)


Maximum absolute change (pp)


I&amp;sup2; range (%)


Sensitivity inference




Undiagnosed hypertension


46.4


44.9&amp;ndash;48.4


1.97


99.6&amp;ndash;99.7


Stable




Uncontrolled among treated


49.6


46.5&amp;ndash;53.9


4.22


98.5&amp;ndash;99.5


Moderately sensitive




Uncontrolled among all hypertensives


78.7


76.0&amp;ndash;81.3


2.62


99.8&amp;ndash;99.9


Stable




Awareness/diagnosis


52.5


49.3&amp;ndash;55.6


3.17


99.6&amp;ndash;99.7


Moderately sensitive




Treatment


43.5


39.6&amp;ndash;47.2


3.86


99.7&amp;ndash;99.8


Moderately sensitive




Control


21.3


18.7&amp;ndash;24.0


2.62


99.8&amp;ndash;99.9


Stable




Reviewer revision: Recheck leave-one-out estimates, CI and absolute percentage-point changes against statistical output
&amp;nbsp;
Table 6: Most Influential Leave-One-Out Exclusions




Meta-analysis pool


Most influential omitted study


Recalculated pooled estimate (%)


95% CI (%)


Change vs main estimate (pp)


Influence




Undiagnosed hypertension


Oliveira et al. [27]


48.4


44.7&amp;ndash;52.0


+1.97


Low




Uncontrolled among treated


Joffres et al. [39] &amp;mdash; Canada


53.9


41.6&amp;ndash;65.7


+4.22


Meaningful




Uncontrolled among all hypertensives


Joffres et al. [39] &amp;mdash; Canada


81.3


74.5&amp;ndash;86.6


+2.61


Low




Awareness/diagnosis


Joffres et al. [39] &amp;mdash; Canada


49.3


44.1&amp;ndash;54.6


&amp;minus;3.17


Meaningful




Treatment


Joffres et al. [39] &amp;mdash; Canada


39.6


33.7&amp;ndash;45.9


&amp;minus;3.86


Meaningful




Control


Cham et al. [18]


24.0


17.3&amp;ndash;32.2


+2.62


Low




Reviewer revision: Recheck leave-one-out estimates, CI and absolute percentage-point changes against statistical output
&amp;nbsp;
Author Verification Required before Resubmission
Original search logs and date; PRISMA checklist and exclusion records; protocol registration; full extraction sheet with denominators; risk-of-bias worksheets; GRADE ratings; statistical model and software output; funnel-plot test values; leave-one-out calculations; and bibliographic source verification. These cannot be reconstructed reliably from the manuscript alone.
&amp;nbsp;
The observed results were also consistent with the life-course approach to hypertension diagnostics. Even though this review focused primarily on adult population-based literature, pediatric and youth populations' literature had emphasized that high blood pressure may be under-diagnosed before the adulthood [46]. Also, high-risk pediatric populations had needed the active blood pressure surveillance [47,48]. In this review, younger adults were more frequently under-diagnosed despite their lower hypertension prevalence, which could imply the low perception of risk and rare healthcare contact.
&amp;nbsp;
High burden of treated-uncontrolled hypertension might have been explained by non-adherence, therapeutic inertia, follow-up, and the bias of office-based blood pressure measurement. Non-adherence had been common in resistant hypertension [49], and the national hypertension literature had emphasized the persistence of control gap even in developed healthcare systems [50]. The role of nocturnal hypertension, home monitoring, ambulatory monitoring, and asleep BP profile had been increasingly recognized in recent literature [51-54]. The very high heterogeneity across the pooled outcomes (I&amp;sup2; = 99.5-99.9%) was predictable since the studies differed in terms of region, age range, survey year, blood pressure protocol, denominator definition, and healthcare system. However, the direction of evidence had been consistent enough to support the importance of standardization of BP measurement, phenotype identification, and integration of cardiometabolic care [55-59].
&amp;nbsp;
Limitations
Considerable statistical heterogeneity was present across majority of the included studies in this review with respect to pooled outcomes owing to variations in geography, age, eligibility, sampling approach, data collection period, methodology for blood pressure assessment, denominators, and outcome measures. Some studies reported cascade outcomes rather than undiagnosed or uncontrolled hypertension estimates, necessitating the transformation of relevant outcomes from awareness, treatment, or control rates. Most of the included studies had cross-sectional designs, which precluded investigation of temporal consistency, compliance with the treatment, and causal factors leading to under-diagnosis or poor control. The results were also conditional upon the health care system context since national surveys, studies of older-adult populations, samples of people in the working ages, and multi-country community surveys were not entirely comparable despite the standardized pooling.</p></sec><sec><title>CONCLUSION</title><p>This systematic review and meta-analysis demonstrated that undiagnosed and uncontrolled hypertension were large unresolved problems in global cardiovascular disease prevention. The results of the pooled analysis implied that undiagnosed condition was prevalent among more than half of patients with hypertension, whereas effective population control rates were low. It was evident that the entire continuum of hypertension care had suffered from sequential loss to follow-up at the levels of screening, diagnosis, treatment, and control of the condition.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal">Burnier M. and A. Damianaki. &amp;ldquo;Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease.&amp;rdquo; Circ Res, vol. 132, no. 8, 2023, pp. 1050-1063. https://doi.org/10.1161/CIRCRESAHA.122.321762.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal">Shalaeva E.V. and F. H. Messerli. &amp;ldquo;What Is Resistant Arterial Hypertension?&amp;rdquo; Blood Press, vol. 32, no. 1, 2023, article 2185457. https://doi.org/10.1080/08037051.2023.2185457.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal">Falkner B. et al. &amp;ldquo;Pediatric Primary Hypertension: An Underrecognized Condition: A Scientific Statement from the American Heart Association.&amp;rdquo; Hypertension, vol. 80, no. 6, 2023. https://doi.org/10.1161/HYP.0000000000000228.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal">Liu J. et al. &amp;ldquo;Asian Expert Consensus on Nocturnal Hypertension Management.&amp;rdquo; Hypertension, vol. 82, no. 6, 2025, pp. 945-956. https://doi.org/10.1161/HYPERTENSIONAHA.124.24026.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal">Funder J. &amp;ldquo;Primary Aldosteronism.&amp;rdquo; Trends Cardiovasc Med, vol. 32, no. 4, 2022, pp. 228-233. https://doi.org/10.1016/j.tcm.2021.03.005.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal">Henning R.J. and W. M. Anderson. &amp;ldquo;Sleep Apnea Is a Common and Dangerous Cardiovascular Risk Factor.&amp;rdquo; Curr Probl Cardiol, vol. 50, no. 1, 2025, article 102838. https://doi.org/10.1016/j.cpcardiol.2024.102838.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal">Symonides B. et al. &amp;ldquo;Resistant Hypertension in Dialysis.&amp;rdquo; Nephrol Dial Transplant, vol. 38, no. 9, 2023, pp. 1952-1959. https://doi.org/10.1093/ndt/gfad047.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal">Parodi R. et al. &amp;ldquo;Resistant Hypertension: Diagnosis, Evaluation, and Treatment Practical Approach.&amp;rdquo; Eur J Intern Med, vol. 123, 2024, pp. 23-28. https://doi.org/10.1016/j.ejim.2023.12.026.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal">Gibson M. et al. &amp;ldquo;The Association between 24-Hour Blood Pressure Profiles and Dementia.&amp;rdquo; J Alzheimers Dis, vol. 94, no. 4, 2023, pp. 1303-1322. https://doi.org/10.3233/JAD-230400.</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal">Yahr J. et al. &amp;ldquo;Resistant Hypertension: A Stepwise Approach.&amp;rdquo; Cleve Clin J Med, vol. 90, no. 2, 2023, pp. 115-125. https://doi.org/10.3949/ccjm.90a.22046.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal">Mousavi S.S. et al. &amp;ldquo;A Survey on Blood Pressure Measurement Technologies: Addressing Potential Sources of Bias.&amp;rdquo; Sensors (Basel), vol. 24, no. 6, 2024, article 1730. https://doi.org/10.3390/s24061730.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal">Smith A.P. et al. &amp;ldquo;Target: BP&amp;trade;: A National Initiative to Improve Blood Pressure Control.&amp;rdquo; Hypertension, vol. 80, no. 12, 2023, pp. 2523-2532. https://doi.org/10.1161/HYPERTENSIONAHA.123.20389.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal">Page M.J. et al. &amp;ldquo;PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews.&amp;rdquo; BMJ, vol. 372, 2021, article n160. https://doi.org/10.1136/bmj.n160.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal">Downes M.J. et al. &amp;ldquo;Development of a Critical Appraisal Tool to Assess the Quality of Cross-Sectional Studies (AXIS).&amp;rdquo; BMJ Open, vol. 6, no. 12, 2016, article e011458. https://doi.org/10.1136/bmjopen-2016-011458.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal">Lo C.K. et al. &amp;ldquo;Newcastle-Ottawa Scale: Comparing Reviewers' to Authors' Assessments.&amp;rdquo; BMC Med Res Methodol, vol. 14, 2014, article 45. https://doi.org/10.1186/1471-2288-14-45.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal">Bezerra C.T. et al. &amp;ldquo;Assessment of the Strength of Recommendation and Quality of Evidence: GRADE Checklist. A Descriptive Study.&amp;rdquo; Sao Paulo Med J, vol. 140, no. 6, 2022, pp. 829-836. https://doi.org/10.1590/1516-3180.2022.0043.R1.07042022.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal">Fekete J.T. and B. Győrffy. &amp;ldquo;MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies.&amp;rdquo; J Med Internet Res, vol. 27, 2025, article e64016. https://doi.org/10.2196/64016.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal">Cham B. et al. &amp;ldquo;Burden of Hypertension in The Gambia: Evidence from a National World Health Organization STEP Survey.&amp;rdquo; Int J Epidemiol, vol. 47, no. 3, 2018, pp. 860-871.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal">Pengpid S., and K. Peltzer. &amp;ldquo;Undiagnosed Hypertension in Sudan: Results of the Cross-Sectional National STEPS Survey in 2016.&amp;rdquo; Pan Afr Med J, vol. 42, 2022, article 205.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal">Odili A.N. et al. &amp;ldquo;Prevalence, Awareness, Treatment and Control of Hypertension in Nigeria: Data from a Nationwide Survey 2017.&amp;rdquo; Glob Heart, vol. 15, no. 1, 2020, article 47.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal">Rannan-Eliya R.P. et al. &amp;ldquo;Hypertension Diagnosis, Awareness, Treatment, and Control in Sri Lanka.&amp;rdquo; BMC Public Health, vol. 25, 2025, article 1417.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal">Matar D. et al. &amp;ldquo;Prevalence, Awareness, Treatment, and Control of Hypertension in Lebanon.&amp;rdquo; J Clin Hypertens, vol. 17, no. 5, 2015, pp. 381-388.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal">Saeed A.A. et al. &amp;ldquo;Prevalence, Awareness, Treatment, and Control of Hypertension among Saudi Adult Population: A National Survey.&amp;rdquo; Int J Hypertens, vol. 2011, 2011, article 174135.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal">Uherni, A.I. et al. &amp;ldquo;Undiagnosed Hypertension in Croatia.&amp;rdquo; Croat Med J, vol. 64, no. 1, 2023, pp. 24-31.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal">Campbell E. et al. &amp;ldquo;Sociodemographic and Health-Related Differences in Undiagnosed Hypertension in the Health Survey for England 2015&amp;ndash;2019: A Cross-Sectional Cohort Study.&amp;rdquo; eClinicalMedicine, vol. 66, 2023, article 102333.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal">Salazar Fl&amp;oacute;rez J.E. et al. &amp;ldquo;Burden of Undiagnosed Hypertension and Its Associated Factors: A Challenge for Primary Health Care in Urban Colombia.&amp;rdquo; PLoS One, vol. 18, no. 11, 2023, article e0294177.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal">Oliveira, I.M. et al. &amp;ldquo;Prevalence of Systemic Arterial Hypertension Diagnosed, Undiagnosed, and Uncontrolled in Elderly Population: SABE Study.&amp;rdquo; J Aging Res, vol. 2019, 2019, article 3671869.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal">Dieteren, C.M. et al. &amp;ldquo;Prevalence and Inequality in Persistent Undiagnosed, Untreated, and Uncontrolled Hypertension: Evidence from a Cohort of Older Mexicans.&amp;rdquo; PLOS Glob Public Health, vol. 1, no. 12, 2021, article e0000114.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal">Guerrero-D&amp;iacute;az, D.V. et al. &amp;ldquo;Undiagnosed Hypertension in Peru: Analysis of Associated Factors and Socioeconomic Inequalities, 2019.&amp;rdquo; Heliyon, vol. 7, no. 7, 2021, article e07516.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal">Rahim, N.A.A. et al. &amp;ldquo;Undiagnosed Hypertension: A Silent Epidemic among Middle-Aged and Older Adults with Elevated Blood Pressure in Malaysia.&amp;rdquo; Asia Pac J Public Health, vol. 37, no. 6, 2025, article 10105395251340928.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal">Mahwati, Y. et al. &amp;ldquo;The Determinants of Undiagnosed Hypertension among Indonesian Adults: A Cross-Sectional Study Based on the 2014&amp;ndash;2015 Indonesia Family Life Survey.&amp;rdquo; J Prev Med Public Health, vol. 55, no. 1, 2022, pp. 60-67.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal">Mehata, S. et al. &amp;ldquo;Prevalence, Awareness, Treatment and Control of Hypertension in Nepal: Data from Nationally Representative Population-Based Cross-Sectional Study.&amp;rdquo; J Hypertens, vol. 36, no. 8, 2018, pp. 1680-1688.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal">Hasan, M.M. et al. &amp;ldquo;Examining the Prevalence, Correlates and Inequalities of Undiagnosed Hypertension in Nepal: A Population-Based Cross-Sectional Study.&amp;rdquo; BMJ Open, vol. 10, no. 10, 2020, article e037592.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal">Khanam, M.A. et al. &amp;ldquo;Undiagnosed and Uncontrolled Hypertension among the Adults in Rural Bangladesh: Findings from a Community-Based Study.&amp;rdquo; J Hypertens, vol. 33, no. 12, 2015, pp. 2399-2406.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal">Ahmed, S. et al. &amp;ldquo;Inequalities in the Prevalence of Undiagnosed Hypertension among Bangladeshi Adults: Evidence from a Nationwide Survey.&amp;rdquo; Int J Equity Health, vol. 18, no. 1, 2019, article 33.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal">Mohanty, S.K. et al. &amp;ldquo;Awareness, Treatment, and Control of Hypertension in Adults Aged 45 Years and over and Their Spouses in India: A Nationally Representative Cross-Sectional Study.&amp;rdquo; PLoS Med, vol. 18, no. 8, 2021, article e1003740.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal">Das, A. et al. &amp;ldquo;Undiagnosed Hypertension and Its Associated Factors in India: A Rural-Urban Contrast from the National Family Health Survey 2019&amp;ndash;21.&amp;rdquo; PLoS One, vol. 20, no. 5, 2025, article e0316782.</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal">Zhang, M. et al. &amp;ldquo;Prevalence, Awareness, Treatment, and Control of Hypertension in China, 2004&amp;ndash;18: Findings from Six Rounds of a National Survey.&amp;rdquo; BMJ, vol. 380, 2023, article e071952.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal">Joffres, M. et al. &amp;ldquo;Hypertension Prevalence, Awareness, Treatment and Control in National Surveys from England, the USA and Canada, and Correlation with Stroke and Ischaemic Heart Disease Mortality.&amp;rdquo; BMJ Open, vol. 3, 2013, article e003423.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal">Lloyd-Sherlock, P. et al. &amp;ldquo;Hypertension among Older Adults in Low- and Middle-Income Countries: Prevalence, Awareness and Control.&amp;rdquo; Int J Epidemiol, vol. 43, no. 1, 2014, pp. 116-128.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal">Irazola, V. E. et al. &amp;ldquo;Hypertension Prevalence, Awareness, Treatment, and Control in Selected Low- and Middle-Income Communities: Results from the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases.&amp;rdquo; Glob Heart, vol. 11, no. 1, 2016, pp. 47-59.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal">Chow, C.K. et al. &amp;ldquo;Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries.&amp;rdquo; JAMA, vol. 310, no. 9, 2013, pp. 959-968.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal">Lithovius, R. and P. H. Groop. &amp;ldquo;The Many Faces of Hypertension in Individuals with Type 1 Diabetes.&amp;rdquo; Diabetes Res Clin Pract, vol. 197, 2023, article 110564. https://doi.org/10.1016/j.diabres.2023.110564.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal">Karam, S. et al. &amp;ldquo;Approach to Diagnosis and Management of Hypertension: A Comprehensive and Combined Pediatric and Adult Perspective.&amp;rdquo; Semin Nephrol, vol. 43, no. 4, 2023, article 151438. https://doi.org/10.1016/j.semnephrol.2023.151438.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal">Banegas, J.R. et al. &amp;ldquo;Numerical Values and Impact of Hypertension in Spain.&amp;rdquo; Rev Esp Cardiol (Engl Ed), vol. 77, no. 9, 2024, pp. 767-778. https://doi.org/10.1016/j.rec.2024.03.011.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal">Urbina, E.M. et al. &amp;ldquo;Blood Pressure in Children in the 21st Century: What Do We Know and Where Do We Go from Here?&amp;rdquo; Hypertension, vol. 80, no. 8, 2023, pp. 1572-1579. https://doi.org/10.1161/HYPERTENSIONAHA.122.19455.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal">Seeman, T. et al. &amp;ldquo;Isolated Nocturnal Hypertension in Pediatric Kidney Transplant Recipients.&amp;rdquo; Pediatr Transplant, vol. 26, no. 2, 2022. https://doi.org/10.1111/petr.14192.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal">McCarrison, S. et al. &amp;ldquo;The Prevalence of Hypertension in Paediatric Turner Syndrome: A Systematic Review and Meta-Analysis.&amp;rdquo; J Hum Hypertens, vol. 37, no. 8, 2023, pp. 675-688. https://doi.org/10.1038/s41371-022-00777-8.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal">Bourque, G. et al. &amp;ldquo;Nonadherence Is Common in Patients with Apparent Resistant Hypertension: A Systematic Review and Meta-Analysis.&amp;rdquo; Am J Hypertens, vol. 36, no. 7, 2023, pp. 394-403. https://doi.org/10.1093/ajh/hpad013.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal">Banegas, J.R. and T. Gij&amp;oacute;n-Conde. &amp;ldquo;Hypertension: The Most Common Chronic Health Problem in Spain. A Call to Action.&amp;rdquo; Hipertens Riesgo Vasc, vol. 39, no. 3, 2022, pp. 121-127. https://doi.org/10.1016/j.hipert.2022.03.004.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal">Mishra, H.N. et al. &amp;ldquo;Optimizing the Diagnosis and Management of Nocturnal Hypertension: An Expert Consensus from India.&amp;rdquo; J Assoc Physicians India, vol. 73, no. 7, 2025. https://doi.org/10.59556/japi.73.1059.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal">Imai, Y. &amp;ldquo;A Personal History of Research on Hypertension: From an Encounter with Hypertension to the Development of Hypertension Practice Based on Out-of-Clinic Blood Pressure Measurements.&amp;rdquo; Hypertens Res, vol. 45, no. 11, 2022, pp. 1726-1742. https://doi.org/10.1038/s41440-022-01011-1.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal">Nugent, J. et al. &amp;ldquo;Improving Blood Pressure Management and Control with Out-of-Office Blood Pressure Monitoring.&amp;rdquo; Am J Hypertens, vol. 39, no. 5, 2026, pp. 623-631. https://doi.org/10.1093/ajh/hpaf222.</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal">Hermida, R.C. et al. &amp;ldquo;Elevated Asleep Blood Pressure and Non-Dipper 24h Patterning Best Predict Risk for Heart Failure That Can Be Averted by Bedtime Hypertension Chronotherapy: A Review of the Published Literature.&amp;rdquo; Chronobiol Int, vol. 40, no. 1, 2023, pp. 63-82. https://doi.org/10.1080/07420528.2021.1939367.</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal">Flynn, J.T. et al. &amp;ldquo;Practical Approach to Evaluate and Manage Hypertension in Youth: An International Society of Hypertension Position Paper.&amp;rdquo; J Hypertens, vol. 44, no. 4, 2026, pp. 553-571. https://doi.org/10.1097/HJH.0000000000004238.</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal">Kyriakoulis, K. G. et al. &amp;ldquo;Atrial Fibrillation Screening during Routine Automated Office, Home, and Ambulatory Blood Pressure Measurement: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.&amp;rdquo; Hypertension, vol. 81, no. 7, 2024, pp. 1477-1488. https://doi.org/10.1161/HYPERTENSIONAHA.123.22563.</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal">Abdalla, M. et al. &amp;ldquo;Blood Pressure Assessment across the Lifespan: Improving Clinical Research and Clinical Practice: A National Heart, Lung, and Blood Institute Workshop Report.&amp;rdquo; J Am Coll Cardiol, vol. 87, no. 18, 2026, pp. 2524-2542. https://doi.org/10.1016/j.jacc.2026.02.5124.</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal">Zheng, Z. and Z. Yu. &amp;ldquo;From Clinic to Home Monitoring: Diagnostic Strategies and Evidence Landscape of White-Coat Uncontrolled Hypertension.&amp;rdquo; Clin Exp Hypertens, vol. 48, no. 1, 2026, article 2663394. https://doi.org/10.1080/10641963.2026.2663394.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal">Wander, G.S. et al. &amp;ldquo;Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians.&amp;rdquo; J Assoc Physicians India, vol. 72, no. 8, 2024. https://doi.org/10.59556/japi.72.0620.</mixed-citation></ref></ref-list></body></article>